Korean Treatment Guidelines for Metastatic Prostate Cancer Developed by the Korean Association for Clinical Oncology.
10.3904/kjm.2017.92.2.124
- Author:
Inkeun PARK
1
;
Byung Woog KANG
;
Su Jin KOH
;
Kyoung Ha KIM
;
Se Hyun KIM
;
Chan Kyu KIM
;
Ho Young KIM
;
Kwonoh PARK
;
Se Hoon PARK
;
Sung Yong OH
;
Junglim LEE
;
Hyo Jin LEE
;
Seung Taek LIM
;
Jae Cheol JO
;
Jae Lyun LEE
Author Information
1. Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
- Publication Type:Review
- Keywords:
Prostate cancer;
Drug therapy;
Metastasis;
Guideline
- MeSH:
Castration;
Drug Therapy;
Korea;
Medical Oncology*;
Neoplasm Metastasis;
Prostate*;
Prostatic Neoplasms*;
Quality of Life
- From:Korean Journal of Medicine
2017;92(2):124-141
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The management of advanced prostate cancer has evolved rapidly. Androgen deprivation therapy, via surgical or medical castration, is the first-line therapy for hormone-naïve metastatic prostate cancer. For approximately a decade, docetaxel-based chemotherapy was the only approved agent to show a survival benefit for castration-resistant prostate cancer. However, over the last 5 years, significant advances in the field have led to the approval of several new agents with different mechanisms of action, such as the new androgen pathway inhibitors abiraterone and enzalutamide, a new cytotoxic agent, cabazitaxel, and new bone-seeking agents such as radium-223, which have all been associated with improved quality of life and pain palliation and an increase in survival. However, there has been no Korean treatment guideline for metastatic prostate cancer which is developed based on thorough search for relevant articles, including recently developed agents, and adequate review and assessment of evidences, and thus, a guideline adequate for domestic circumstance is eagerly needed. Experts from the Genitourinary Oncology Committee of the Korea Cancer Study Group developed clinical recommendations for the treatment of metastatic prostate cancer based on 19 key questions. The Korean Association for Clinical Oncology, the Korean Prostate Society, the Korean Urological Oncology Society, and the Korean Society of Pathologists reviewed and endorsed the guidelines. These are the first Korean treatment guidelines developed specifically for metastatic prostate cancer.
